Patents by Inventor Peter John Sadler
Peter John Sadler has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 9598448Abstract: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.Type: GrantFiled: March 10, 2016Date of Patent: March 21, 2017Assignee: University of WarwickInventors: Ying Fu, Peter John Sadler, Abraha Habtemariam
-
Publication number: 20160272663Abstract: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.Type: ApplicationFiled: March 10, 2016Publication date: September 22, 2016Applicant: University of WarwickInventors: Ying Fu, Peter John Sadler, Abraha Habtemariam
-
Patent number: 9408853Abstract: The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.Type: GrantFiled: May 20, 2011Date of Patent: August 9, 2016Assignee: University of WarwickInventors: Abraha Habtemariam, Zhe Liu, Joan Josep Soldevila, Ana Maria Pizarro, Peter John Sadler
-
Patent number: 9296772Abstract: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.Type: GrantFiled: April 15, 2011Date of Patent: March 29, 2016Assignee: The University of WarwickInventors: Ying Fu, Peter John Sadler, Abraha Habtemariam
-
Publication number: 20130065864Abstract: The present invention relates to novel iridium and/or rhodium containing complexes for use as a cytotoxic, such as an anti-cancer agent. There is also provided a method of preparing said compounds.Type: ApplicationFiled: May 20, 2011Publication date: March 14, 2013Applicant: UNIVERSITY OF WARWICKInventors: Abraha Habtemariam, Zhe Liu, Joan Josep Soldevila, Ana Maria Pizarro, Peter John Sadler
-
Publication number: 20130040925Abstract: The present invention relates to the use of certain osmium containing complexes such as cytotoxic agents particularly for the treatment of cancer. There is also provided novel osmium containing complexes, as well as pharmaceutical formulations comprising such complexes.Type: ApplicationFiled: April 15, 2011Publication date: February 14, 2013Applicant: UNIVERSITY OF WARWICKInventors: Ying Fu, Peter John Sadler, Abraha Habtemariam
-
Publication number: 20100291236Abstract: The present invention relates to osmium compounds of formula (I), their preparation and use in methods of treatment, particularly for cancer treatment.Type: ApplicationFiled: August 10, 2007Publication date: November 18, 2010Applicant: THE UNIVERSITY OF WARWICKInventors: Peter John Sadler, Anna Frances Acushla Peacock, Sabine Helena Van Rijt, Abraha Habtemariam
-
Publication number: 20090318402Abstract: A ruthenium (II) compound of formula (I) wherein X is halo or a neutral or negatively charged O, N- or S-donor ligand; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; A is either: (i) (Ru)—NRN1RN2—RN3—(N), where RN1 and RN2 are independently selected from H, optionally substituted C1-7alkyl, C3-20 heterocyclyl and C5-20aryl, and RN3 is C1-2alkylene; or (ii) a nitrogen-containing C5-6aromatic ring, wherein the nitrogen ring atom is bound to the ruthenium atom, and the ring is also bound to the azo-nitrogen, either by a single bond wherein the bond is ? or ? to the nitrogen ring atom, or by a —CH2? group wherein the bond is x to the nitrogen ring atom; B is optionally substituted C1-7alkyl, C3-20heterocyclyl or C5-20aryl.Type: ApplicationFiled: March 7, 2007Publication date: December 24, 2009Applicant: The University Court of the University of EdinburgInventors: Sarah Dougan, Abraha Habtemariam, Michael Melchart, Peter John Sadler
-
Publication number: 20090186864Abstract: A ruthenium (II) compound of formula (I): or a solvate form thereof for use in a method of therapy, wherein: R1, R2, R3, R4, R5 and R6 are independently selected from H, C1-7 alkyl, C5-20 aryl, C3-20 heterocyclyl, halo, ester, amido, acyl, sulfo, sulfonamido, ether, thioether, azo and amino, or R1 and R2 together with the ring to which they are attached form a saturated or unsaturated carbocyclic or heterocyclic group containing up to three 3- to 8-membered carbocyclic or heterocyclic rings, wherein each carbocyclic or heterocyclic ring may be fused to one or more other carbocyclic or heterocyclic rings; X is halo or a neutral or negatively charged O, N— or S— donor ligand; Y is a counterion; m is ?1, 0, 1 or 2; q is 1, 2 or 3; RC1 and RC2 independently represent one or more optional substituents selected from hydroxy, C1-7 alkoxy, C5-20 aryloxy, C1-7 alkyl, carboxy, C1-7 alkyl ester and C5-20 aryl ester; RN1 and RN2 are independently selected from hydroxy, C1-7 alkoxy, C5-20 aryloxy, C1-7 alkyl, carboType: ApplicationFiled: May 21, 2007Publication date: July 23, 2009Inventors: Abraha Habtemariam, Tijana Bugarcic, Peter John Sadler
-
Patent number: 7241913Abstract: Ruthenium (II) compounds of formula (I) are useful in the treatment and/or prevention of cancerType: GrantFiled: April 29, 2004Date of Patent: July 10, 2007Assignee: The University Court of the University of EdinburghInventors: Abraha Habtemariam, Peter John Sadler
-
Patent number: 7176327Abstract: The present invention provides a compound of formula (I): PtIV(N3)2X1X2Y1Y2, wherein X1 and X2 are the same or different and each one is a group NR1R2R3 wherein R1, R2 and R3 are the same or different and each can be any one of H and optionally substituted alkyl, aryl, aralkyl, acyl, cycloalkyl, heterocyclyl, alkenyl, aralkenyl, alkinyl, cycloalkenyl, or X1 and X2 together represent a group R1R2NR4NR1R2 wherein R1 and R2 have the same meaning as before, and R4 represents an optionally substituted divalent, saturated or unsaturated, alkyl chain, an optionally substituted divalent, saturated or unsaturated cycloalkyl or an optionally substituted divalent aryl, or R4 or two or more of R1, R2, R3 and R4 and the respective N atom(s) to which they are linked, represent an optionally substituted heterocyclyl having at least one ring containing said N atom(s); and Y1 and Y2 are the same or different or when cis together represent a divalent moiety Y3, wherein at least one of Y1 and Y2, or Y3, is a substantially labilType: GrantFiled: August 27, 2002Date of Patent: February 13, 2007Assignee: University Court of the University of EdinburghInventors: Peter John Sadler, Philippe Muller
-
Patent number: 6979681Abstract: Ruthenium (II) compounds of the formula: wherein: R1 is —CO2CH3; R2, R3, R4, R5 and R6 independently represent H, alkyl, cylcoalkyl, —CO2R?, aryl or alkylaryl, which latter two groups are optionally substituted on the aromatic ring; R? represents alkyl, cylcoalkyl, aryl or alkaryl; X is halo, H2O, (R?)(R?)SO, R?CO2? or (R?)(R?)C?O, where R? represents alkyl, cylcoalkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C? is C1 to C12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently R11—CN, where R? represents alkyl or cycloalkyl; or B is halo and A is 4-substitued pyridine; or p is 0, A is NR7R8 and B is NR9R10wherein R7, R8, R9 and R10 independently represent H, or alkyl, and A and B are linked by an alkylene chain, optionally substituted in or on the alkylene chain; or p is 1, A is NR7 and B is NR9R10, wherein R7, R9 and R10 are as previously defined, and A aType: GrantFiled: May 18, 2004Date of Patent: December 27, 2005Assignee: University Court, The University of EdinburghInventors: Robert Edward Morris, Peter John Sadler, Haimei Chen, Duncan Jodrell
-
Patent number: 6936634Abstract: Compounds which may be used in the treatment and/or prevention of cancer have the formula (I): wherein R1 and R2 together with the ring to which they are bound represent a saturated or unsaturated carbocyclic or heterocyclic groupType: GrantFiled: June 26, 2001Date of Patent: August 30, 2005Assignee: The University Court, The University of Edinburgh (UK)Inventors: Robert Edward Morris, Peter John Sadler, Duncan Jodrell, Haimei Chen
-
Publication number: 20040248873Abstract: The present invention provides a compound of formula (I): PtIV(N3)2X1X2Y1Y2, wherein X1 and X2 are the same or different and each one is a group NR1R2R3 wherein R1, R2 and R3 are the same or different and each can be any one of H and optionally substituted alkyl, aryl, aralkyl, acyl, cycloalkyl, heterocyclyl, alkenyl, aralkenyl, alkinyl, cycloalkenyl, or X1 and X2 together represent a group R1R2NR4NR1R2 wherein R1 and R2 have the same meaning as before, and R4 represents an optionally substituted divalent, saturated or unsaturated, alkyl chain, an optionally substituted divalent, saturated or unsaturated cycloalkyl or an optionally substituted divalent aryl, or R4 or two or more of R1, R2, R3 and R4 and the respective N atom(s) to which they are linked, represent an optionally substituted heterocyclyl having at least one ring containing said N atom(s); and Y1 and Y2 are the same or different or when cis together represent a divalent moiety Y3, wherein at least one of Y1 and Y2, or Y3, is a substantially labilType: ApplicationFiled: February 24, 2004Publication date: December 9, 2004Inventors: Peter John Sadler, Philippe Muller
-
Publication number: 20040220166Abstract: Compounds which may be used in the treatment and/or prevention of cancer have the formula (I) wherein: R1, R2, R3, R4, R5 and R6 independently represents H, alkyl, —CO2R′, aryl or alkylaryl, which latter two groups are optionally substituted on the aromatic ring; R′ represent alkyl, aryl or alkaryl; X is halo, H2O, (R′)(R″)SO, R′CO2— or (R′)(R″)C═O, where R″ represents alkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C′ is C1 to C12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently N-donor nitrile ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR7R8 and B is NR9R10, wherein R7, R8, R9 and R10 independently represent H or alkyl, and A and B are linked by an alkylene chain, optionallyType: ApplicationFiled: May 18, 2004Publication date: November 4, 2004Applicants: University Court, The University of Edinburgh, a United Kingdom corporationInventors: Robert Edward Morris, Peter John Sadler, Haimei Chen, Duncan Jodrell
-
Patent number: 6750251Abstract: Compounds which may be used in the treatment and/or prevention of cancer have the formula (I) wherein: R1, R2, R3, R4, R5 and R6 independently represents H, alkyl, —CO2R′, aryl or akylaryl, which latter two groups are optionally substituted on the aromatic ring; R′ represent alkyl, aryl or alkaryl; X is halo, H2O, (R′)(R″)SO, R′CO2— or (R′)(R″)C═O, where R″ represents alkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C′ is C1 to C12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently N-donor nitrile ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR7R8 and B is NR9R10, wherein R7, R8, R9 and R10 independently represent H or alkyl, and A and B are linked by an alkylene chain, optionally sType: GrantFiled: April 26, 2002Date of Patent: June 15, 2004Assignee: The University Court, The University of Edinburgh (UK)Inventors: Robert Edward Morris, Peter John Sadler, Haimei Chen, Duncan Jodrell
-
Publication number: 20040029852Abstract: Compounds which may be used in the treatment and/or prevention of cancer have the formula (I): wherein R1 and R2 together with the ring to which they are bound represent a saturated or unsaturated carbocyclic or heterocyclic group.Type: ApplicationFiled: August 15, 2003Publication date: February 12, 2004Inventors: Robert Edward Morris, Peter John Sadler, Duncan Jodrell, Haimei Chen
-
Publication number: 20030023088Abstract: Compounds which may be used in the treatment and/or prevention of cancer have the formula (I) wherein: R1, R2, R3, R4, R5 and R6 independently represents H, alkyl, —CO2R′, aryl or akylaryl, which latter two groups are optionally substituted on the aromatic ring; R′ represent alkyl, aryl or alkaryl; X is halo, H2O, (R′)(R″)SO, R′CO2— or (R′)(R″)C═O, where R″ represents alkyl, aryl or alkaryl; Y is a counterion; m is 0 or 1; q is 1, 2 or 3; C′ is C1 to C12 alkylene, optionally substituted in or on the alkylene chain, bound to two A groups; p is 0 or 1 and r is 1 when p is 0 and r is 2 when p is 1; and A and B are: each independently N-donor nitrite ligands; or B is halo and A is an N-donor pyridine ligand, optionally substituted at one or more of the carbon atoms of the pyridine ring; or p is 0, A is NR7R8 and B is NR9R10, wherein R7, R8, R9 and R10 independently represent H or alkyl, and A and B are linked by an alkylene chain, optionally sType: ApplicationFiled: April 26, 2002Publication date: January 30, 2003Inventors: Robert Edward Morris, Peter John Sadler, Haimei Chen, Duncan Jodrell